

-> b reg
 FILE 'REGISTRY' ENTERED AT 18:18:59 ON 03 MAR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7
 DICTIONARY FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

-> d que sta 19



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
 L7 908950 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES
 L9 739 SEA FILE=REGISTRY SUB=L7 SSS FUL L5

100.0% PROCESSED 222075 ITERATIONS
 SEARCH TIME: 00.00.06

739 ANSWERS

-> b hcap
 FILE 'HCAPIUS' ENTERED AT 18:19:18 ON 03 MAR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Mar 2008 VOL 148 ISS 10
FILE LAST UPDATED: 2 Mar 2008 (20080302/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhltstr l12 tot

111 ANNNNN 1 OF 1 HCNPLMUS COPYRIGHT 2016 ACS on STM

AN 1111-111111

OR 1111-111111

12 Preparation of heterocycloalkylmethylindolines and related compounds as

13 Cys receptor modulators for the treatment of inflammatory disorders

14 (Chem. Abstr.: Res. Chem. Soc. Hong. (London, England, George)

15 Hertzog, Chantana, Hiltner, Robert; Peterson, John M.

16 Heterocyclic Corporation, KRM

17 1111-1111 1111-1111

18 1111-1111 1111-1111

19 1111-1111 1111-1111

20 1111-1111 1111-1111

21 1111-1111 1111-1111

22 1111-1111 1111-1111

23 1111-1111 1111-1111

24 1111-1111 1111-1111

25 1111-1111 1111-1111

26 1111-1111 1111-1111

27 1111-1111 1111-1111

28 1111-1111 1111-1111

29 1111-1111 1111-1111

30 1111-1111 1111-1111

31 1111-1111 1111-1111

32 1111-1111 1111-1111

33 1111-1111 1111-1111

34 1111-1111 1111-1111

35 1111-1111 1111-1111

36 1111-1111 1111-1111

37 1111-1111 1111-1111

38 1111-1111 1111-1111

39 1111-1111 1111-1111

40 1111-1111 1111-1111

41 1111-1111 1111-1111

42 1111-1111 1111-1111

43 1111-1111 1111-1111

44 1111-1111 1111-1111

45 1111-1111 1111-1111

46 1111-1111 1111-1111

47 1111-1111 1111-1111

48 1111-1111 1111-1111

49 1111-1111 1111-1111

50 1111-1111 1111-1111

51 1111-1111 1111-1111

52 1111-1111 1111-1111

53 1111-1111 1111-1111

54 1111-1111 1111-1111

55 1111-1111 1111-1111

56 1111-1111 1111-1111

57 1111-1111 1111-1111

58 1111-1111 1111-1111

59 1111-1111 1111-1111

60 1111-1111 1111-1111

61 1111-1111 1111-1111

62 1111-1111 1111-1111

63 1111-1111 1111-1111

64 1111-1111 1111-1111

65 1111-1111 1111-1111

66 1111-1111 1111-1111

67 1111-1111 1111-1111

68 1111-1111 1111-1111

69 1111-1111 1111-1111

70 1111-1111 1111-1111

71 1111-1111 1111-1111

72 1111-1111 1111-1111

73 1111-1111 1111-1111

74 1111-1111 1111-1111

75 1111-1111 1111-1111

76 1111-1111 1111-1111

77 1111-1111 1111-1111

78 1111-1111 1111-1111

79 1111-1111 1111-1111

80 1111-1111 1111-1111

81 1111-1111 1111-1111

82 1111-1111 1111-1111

83 1111-1111 1111-1111

84 1111-1111 1111-1111

85 1111-1111 1111-1111

86 1111-1111 1111-1111

87 1111-1111 1111-1111

88 1111-1111 1111-1111

89 1111-1111 1111-1111

90 1111-1111 1111-1111

91 1111-1111 1111-1111

92 1111-1111 1111-1111

93 1111-1111 1111-1111

94 1111-1111 1111-1111

95 1111-1111 1111-1111

96 1111-1111 1111-1111

97 1111-1111 1111-1111

98 1111-1111 1111-1111

99 1111-1111 1111-1111

100 1111-1111 1111-1111

112 ANNNNN 1 OF 1 HCNPLMUS COPYRIGHT 2016 ACS on STM

(Continued)

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

112111-1111 1111-1111

* SYNTHESIS REACTION TWO WANTS FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AN 1111-1111 1111-1111

OR 1111-1111 1111-1111

12 Preparation of heterocycloalkylmethylindolines and related compounds as

13 Cys receptor modulators for the treatment of inflammatory disorders


14 (Chem. Abstr.: Res. Chem. Soc. Hong. (London, England, George)

-> d bib abs hitstr 128 tot

-> d bib abs hitstr 124 tot

124 ANSWER 1 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)

CM 1
 CHE 179332-16-2
 CHE C12 H22 F N3




CM 2
 CHE 115-16-7
 CHE C4 H6 O4

Double bond geometry as shown:



RM 179332-16-5 NCAPLES
 CM Piperidine, 4-((2-(2-methylphenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)



● 2 HCl

RM 179332-16-5 NCAPLES
 CM Piperidine, 3-((2-(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)



● 2 HCl

RM 179332-27-6 NCAPLES
 CM Piperidine, 4-((2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)


124 ANSWER 1 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)

CM 115-16-7
 CHE C4 H6 O4

Double bond geometry as shown:




RM 179332-21-3 NCAPLES
 CM Piperidine, 4-((2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)




● 2 HCl

RM 179332-33-9 NCAPLES
 CM Piperidine, 4-((2-(2-fluorophenyl)methyl)-1-((2-phenyl-1H-imidazol-4-yl)methyl)-1H-imidazol-4-yl)methyl)-, dihydrochloride (HCl) (CA INDEX NAME)



● 2 HCl

RM 179332-38-6 NCAPLES
 CM Piperidine, 4-((2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)




RM 179332-38-6 NCAPLES
 CM Piperidine, 4-((2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)

CM 1
 CHE 179332-38-6
 CHE C22 H24 F N3




124 ANSWER 1 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)



RM 179332-26-6 NCAPLES
 CM Piperidine, 4-((2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)-, dihydrochloride (HCl) (CA INDEX NAME)

CM 1
 CHE 179332-11-9
 CHE C12 H14 F N3




CM 2
 CHE 115-16-7
 CHE C4 H6 O4

Double bond geometry as shown:




RM 179332-28-7 NCAPLES
 CM Piperidine, 3-((2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)



RM 179332-30-9 NCAPLES
 CM Piperidine, 3-((2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-, dihydrochloride (HCl) (CA INDEX NAME)

CM 1
 CHE 179332-25-7
 CHE C12 H14 F N3



CM 2


124 ANSWER 1 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)

CM 2
 CHE 115-16-7
 CHE C4 H6 O4


Double bond geometry as shown:



RM 179332-44-6 NCAPLES
 CM Piperidine, 3-((2-(2-phenyl-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-1H-imidazol-4-yl)methyl)-, dihydrochloride (HCl) (CA INDEX NAME)



RM 179332-43-9 NCAPLES
 CM Piperidine, 3-((2-(2-phenyl-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-1H-imidazol-4-yl)methyl)-, dihydrochloride (HCl) (CA INDEX NAME)



● 2 HCl

RM 179332-44-9 NCAPLES
 CM Piperidine, 3-((2-(2-phenyl-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-1H-imidazol-4-yl)methyl)-, dihydrochloride (HCl) (CA INDEX NAME)



RM 179332-46-4 NCAPLES
 CM Piperidine, 3-((2-(2-phenyl-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-1H-imidazol-4-yl)methyl)-, dihydrochloride (HCl) (CA INDEX NAME)


RM 179332-46-4 NCAPLES
 CM Piperidine, 3-((2-(2-phenyl-1H-imidazol-4-yl)methyl)-4-(phenylmethyl)-1H-imidazol-4-yl)methyl)-, dihydrochloride (HCl) (CA INDEX NAME)




124 ASSEMBY 1 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)



RD 179323-19-6 NCAPLES
CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (PCT) (CA INDEX NAME)



RD 179323-21-1 NCAPLES
CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (PCT) (CA INDEX NAME)



RD 179323-22-6 NCAPLES
CN 4-Piperidine, 4-(4-chlorophenyl)-1-(2-oxo-3-(2-phenyl-1H-imidazol-4-yl)-2-propenyl)- (PCT) (CA INDEX NAME)



RD 179323-23-0 NCAPLES
CN 4-Piperidine, 4-(4-chlorophenyl)-1-(3-(2-phenyl-1H-imidazol-4-yl)propyl)- (PCT) (CA INDEX NAME)



RD 179323-24-7 NCAPLES
CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (PCT) (CA INDEX NAME)



124 ASSEMBY 2 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)



RD 179323-25-0 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (PCT) (CA INDEX NAME)



RD 179323-25-4 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)




RD 179323-25-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)



RD 179323-26-1 NCAPLES
CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (PCT) (CA INDEX NAME)




RD 179323-26-6 NCAPLES
CN Piperidine, 4-phenyl-1-(2-phenyl-1H-imidazol-4-yl)methyl)- (PCT) (CA INDEX NAME)



124 ASSEMBY 1 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)

RD 179323-27-6 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)



RD 179323-28-1 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (PCT) (CA INDEX NAME)



RD 179323-29-2 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (PCT) (CA INDEX NAME)



RD 179323-30-5 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (PCT) (CA INDEX NAME)




RD 179323-31-6 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (PCT) (CA INDEX NAME)



RD 179323-32-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)



124 ASSEMBY 2 OF 10 NCAPLES COPYRIGHT 2008 ACS on STM (Continued)




RD 179323-32-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)




RD 179323-32-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)




RD 179323-32-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)




RD 179323-32-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)




RD 179323-32-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)



RD 179323-32-7 NCAPLES
CN Piperidine, 1-[(2-methyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenylmethyl- (PCT) (CA INDEX NAME)


[illegible][illegible]

CS Urea, N'-methyl-N-[1-[5-methyl-2-[4-methylphenyl]-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-phenyl)- (SCI) (CA INDEX NAME)




UN 44443-30-9 HCAFLUS
CN Urea, N'-methyl-N-(phenylmethyl)-N-[1-[1-(5-phenyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-6-piperidinyl]- (9CI)

124 APPENDIX 2 OF 10: SCAPUS COPYRIGHT 2008 ACS on STN (Continued)




OS Urea, N⁶-methyl-N⁶-[2-[4-methyl-2-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-2H-imidazol-5-yl]methyl]-8-piperidyl]-N




```

NN  864463-32=1  NCAPLAW
CN  Urea, N-[1-[4-methyl-2-[4-methylphenyl]-2H-inidazol-4-yl)methyl]-
    piperidinyl]-N'-phenyl-N-(phenylmethyl)- (SCI) (CA INDEX NAME)


```





IN 000003-33-2 HCAPLUS
CH Urea, N-[2-[(4-methyl)-2-[(4-(trifluoromethyl)phenyl)-2H-tetrazol-4-yl)methyl]-6-piperidinyl]-N'-[4-methoxyphenyl]-N-(phenylmethyl)- (OCl) (2R)
 new. MAM.




CN 444443-34-3 KCAFLUS
 Urea, N-[1-[[2-(2-methoxyphenyl)-5-methyl-2H-imidazol-4-yl]methyl]
 pyridin-2-yl]-N-methyl-N-(phenylmethyl)- (SCI) (CA THREE NAME)




124 ANSWER 3 OF 10: BCAR166 COPYRIGHT 2008 ACS on 6TH (CircLeand)

CCN(CC)CCOC(=O)C1=CC=C(C=C1)C(=O)N2C=CC=CC=C2

00000000-0000-0000-0000-00000000




000 000000-50-7 NOCAPLSS




NO 66663-55-2 NCAFLUX
CN Urea, N-(4-methoxyphenyl)-N'-methyl-N-[(5-methyl-2-phenyl-3H-imidazol-4-

Page 11


124 ANSWER 3 OF 10 HCAPLES COPYRIGHT 2008 ACS on STM (Continued)




RD 46663-34-9 HCAPLES
CN Urea, N-[1-[(3-(4-methoxyphenyl)-1-methyl-1H-imidazol-4-yl)methyl]-4-piperidin-1-yl]methoxy-N-phenyl- (FCI) (CA INDEX NAME)



RD 46663-37-0 HCAPLES
CN Urea, N'-methoxy-N-phenyl-N-[1-[(4-(4-trifluoromethylphenyl)-1H-imidazol-5-yl)methyl]-4-piperidin-1-yl]methyl- (FCI) (CA INDEX NAME)




RD 46663-38-3 HCAPLES
CN Urea, N-[1-[(3-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-piperidin-1-yl]methoxy-N-phenyl- (FCI) (CA INDEX NAME)




RD 46663-39-5 HCAPLES
CN Urea, N-[1-[(3-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-piperidin-1-yl]methoxy-N-phenyl- (FCI) (CA INDEX NAME)


124 ANSWER 3 OF 10 HCAPLES COPYRIGHT 2008 ACS on STM (Continued)




RD 46663-40-3 HCAPLES
CN Urea, N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N-2-propoxy-N- (FCI) (CA INDEX NAME)




RD 46664-23-9 HCAPLES
CN Urea, N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N'-(4-(trifluoromethylphenyl)- (FCI) (CA INDEX NAME)



RD 46664-25-5 HCAPLES
CN Urea, N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N'-N-phenyl- (FCI) (CA INDEX NAME)




RD 46664-26-6 HCAPLES
CN Urea, N'-N-phenyl-N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenyl- (FCI) (CA INDEX NAME)




RD 46664-27-3 HCAPLES
CN Urea, N'-N-phenyl-N'-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N- (FCI) (CA INDEX NAME)


124 ANSWER 3 OF 10 HCAPLES COPYRIGHT 2008 ACS on STM (Continued)




RD 46663-40-5 HCAPLES
CN Urea, N'-methoxy-N-phenyl-N-[1-[(3-phenyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenyl- (FCI) (CA INDEX NAME)



RD 46663-42-7 HCAPLES
CN Urea, N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N'-(4-nitrophenyl)-N-2-propoxy- (FCI) (CA INDEX NAME)



RD 46663-44-9 HCAPLES
CN Urea, N-[1-[(3-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-piperidin-1-yl]methoxy-N-phenyl- (FCI) (CA INDEX NAME)



RD 46663-45-8 HCAPLES
CN Urea, N-[1-[(3-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]methoxy-N-phenylmethoxy- (FCI) (CA INDEX NAME)

124 ANSWER 3 OF 10 HCAPLES COPYRIGHT 2008 ACS on STM (Continued)



RD 46664-28-8 HCAPLES
CN Urea, N'-methyl-N'-methyl-N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N-2-propoxy-N- (FCI) (CA INDEX NAME)



RD 46664-29-2 HCAPLES
CN Urea, N'-methyl-N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N-2-propoxy-N- (FCI) (CA INDEX NAME)



RD 46664-29-4 HCAPLES
CN Urea, N'-methyl-N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N-2-propoxy-N- (FCI) (CA INDEX NAME)




RD 46664-30-6 HCAPLES
CN Urea, N-[1-(4-methoxyphenyl)methyl]-N'-methyl-N-[1-[(3-methyl-2-(4-(trifluoromethylphenyl)-1H-imidazol-4-yl)methyl)-4-piperidin-1-yl]phenylmethoxy]-N-2-propoxy-N- (FCI) (CA INDEX NAME)


124 ANIMOS 2 OF 10 REPAIRED COPYRIGHT 2009 ACS OR STM (CLASSIFIED)




124 ANSWER 3 OF 10 KCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




RD 16644-11-7 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)



RD 16644-12-8 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-13-9 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-14-0 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)

124 ANSWER 3 OF 10 KCAPLUS COPYRIGHT 2008 ACS on STM (Continued)


OR Draw, N-[1-(4-chlorophenyl)-1H-imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-15-5 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)



RD 16644-16-6 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-17-7 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-18-8 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)

124 ANSWER 3 OF 10 KCAPLUS COPYRIGHT 2008 ACS on STM (Continued)


(NCE) (CA INDEX NAME)




RD 16644-15-5 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)



RD 16644-16-6 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-17-7 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-18-8 KCAPLUS

124 ANSWER 3 OF 10 KCAPLUS COPYRIGHT 2008 ACS on STM (Continued)


(NCE) (CA INDEX NAME)




RD 16644-19-9 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)



RD 16644-20-0 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-21-1 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)




RD 16644-22-2 KCAPLUS
 OR Draw, N-[1-(4-chlorophenyl)imidazol-2-yl]-4-(4-chlorophenyl)-1H-imidazol-4-ylmethyl-4-piperidinyl-N'-phenyl- (NCE) (CA INDEX NAME)


124 ANSWER 3 OF 10 EXAMPLES COPYRIGHT 2009 ACS OF STM (CONTINUED)




OS 044466-4-5 NCARLOS
CS Urea, N¹-methyl-N-[2-methylpropyl]-N-[1-[(15-methyl-2-[5-
(trifluoromethyl)propyl]-1H-imidazol-4-yl)methyl]-L-piperidinyl]- (9CI)
(CA INDEX NAME)



CS Urea, 8-cyclopropyl-8'-methyl-8-[1-[(5-methyl-2-[4-(trifluoromethyl)phenyl]-3H-imidazol-4-yl)methyl]-4-piperidinyl]- (9CI) (CA 120225 HANSE)




235 000000-00-7 HCAPLANS
 236 Urea, N'-[2,4-dichlorophenyl]-N-[1-[[5-methyl-2-[[4-
 (tris[isopropenyl]phenyl]-3H-imidazo[4,5-f][1,2,4]oxadiazol-6-yl)methyl]-4-piperidinyl]-N-
 (oxalodimethyl)-SC(1) (CA INDEX NAME)




064444-70-0 CASNAME
Benzole acid, 4-[[[1111-[[5-methyl-2-[[6-[[trifluoromethyl]phenyl]-1H-imidazo-
4-yl]methyl]-4-piperidinyl](phenylmethyl)amino]carboxyl]amino]-, methyl
ester (HCl) (CA INDEX NAME)


124 ASHER 2 OF 16 HCAPUS COPYRIGHT 2016 ACS on STN (Continued)




SS 066666-37-1 ECAPLOS
 CS Thioresa, N'-methyl-N-[1-[(15-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-phenyl-, (SCI) (CA INDEX NAME)



OS Urea, N-[1-[15-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-[4-phenoxyphenylmethyl]-N'-phenyl- (9C)
(CA INDEX NAME)




006 444445-19-8 KOPFLON
006 Urea, N'-methyl-N-[[[5-methyl-1-(phenylmethyl)-2-(4-
trifluoromethylphenyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-
[(phenylmethyl)- (CA INDEX NAME)




C5 Urea: N-(cyclooctylmethyl)-N'-methyl-N-[3-[[5-methyl-2-[(4-(trifluoromethyl)phenyl)-3H-imidazol-4-yl)methyl]-6-piperidinyl]-9CI] (CA, TOSOL, DASH)


124 ASSAYS 2 OF 10 SAMPLED COPYRIGHT 2009 ACS OR STM (UNCLASSIFIED)




CS 004666-71-1 HCARLOS
Gree, S-(4-chlorophenyl)-8-methyl-8'-[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-10-undecyl-6-yl]methyl]-6-piperidyl]-8'-phenylacetate]-(3Cl) (CA INDEX NAME)



CS 496664-72-2 BCAFPLUS
 Urea, N-methyl-N'-[1-[15-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N,N'-bis(phenylmethyl)- (9CI) (CA, INDEX, NAME)




CS 044464-72-3 ICARLSS
Urea, N'-cyclopropyl-N-[1-[15-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-4-piperidyl]-N-(phenylamthyl)- (9CI) (CA INDEX NAME)




CS 03644461-74-4 BCAFLO5
Urea, N-[1-[1-(3-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-6-piperidyl]-N-(phenylmethyl)-N'-(3-phenylpropyl)- (BCI) (CA 130459) (NMF)


124 ANSWER 3 OF 10: SCAPLES. COPYRIGHT 2008 ACS on STM (Continued)




RX 000000-12-3 HCAPLUS
 CS Benzoic acid, 4-[[[1-[5-methyl-2-[[6-(trifluoromethyl)phenyl]-1H-imidazo-4-yl]methyl]-4-piperidinyl](phenylmethyl)amino]carbonyl]amino)- (NCE)
 TRVW, RWBY



CS 12a, N-[(4-methylphenyl)methyl]-N-[1-[(5-methyl-2-[(4-(trifluoromethyl)phenyl]-2H-imidazol-4-yl)methyl]-1-piperidyl]-3'-phenoxy]-2,2,2-trifluoroethane-1-carboxamide, 12a



RX 000005-24-0 HCAPLAIN
 CH Urea, N-[(2,4-dimethylphenyl)methyl]-N-[1-[(5-methyl-2-[(4-
 (trifluoromethyl)phenyl)-1H-imidazol-5-yl)methyl]-4-piperidinyl]-8'-phenyl-
 (9CI) (QA TRIPLE NAME)



CS 004465-15-6 BOARLUS
Urea, 30'-methyl-8-[1-[[5-methyl-2-[[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-f][1,2,4]triazol-6-yl]methyl]-4-piperidinyl]-N-(2,4,6-trimethoxyphenyl)methyl]- (923) (CS 1806) (SMI)

124 ASSIGNMENT 3 OF 10 RECAPLED COPYRIGHT 2009 ACS ON BTH (CONTINUED)



124 ANSWER 2 OF 10 SCAPUS COPYRIGHT 2004 ACS on 5TH (Continued)
INDEX NAME]




124 ANSWER 3 OF 10 RECAPTED COPYRIGHT 2009 ACS OR ETH (C06C1866d)



124 ANSWER 3 OF 10 BGA7185 COPYRIGHT 2004 ACS on STM (Continued)



124 ANNEK 3 OF 10 KEMULAS COPYRIGHT 2008 ACS on STM (Continued)
 (1-methyl-4-(piperidin-1-yl)-N-(phenylmethyl)-N'-4-pyridinyl)-N'-C1 (CA INDEX NAME)




124-1 ANNEK 3-1-3 KEMULAS
 Dose, N=1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-4-pyridinyl)-N'-C1 (CA INDEX NAME)



124-2 ANNEK 3-1-4 KEMULAS
 Dose, N=1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-3 ANNEK 3-1-5 KEMULAS
 Dose, N=1-[1-(5-methyl-2-(4-(3-chloro-2-pyridin-1-yl)-1-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)




124-4 ANNEK 3-1-6 KEMULAS
 Dose, N=1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-4-pyridinyl)-N'-C1 (CA INDEX NAME)




124 ANNEK 3 OF 10 KEMULAS COPYRIGHT 2008 ACS on STM (Continued)


124-5 ANNEK 4-1-3 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-6 ANNEK 4-1-4 KEMULAS
 Dose, N=1-[1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-7 ANNEK 4-1-5 KEMULAS
 Dose, N=1-[1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)




124-8 ANNEK 4-1-6 KEMULAS
 Dose, N=1-[1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)




124-9 ANNEK 4-1-7 KEMULAS
 Dose, N=1-[1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)




124 ANNEK 3 OF 10 KEMULAS COPYRIGHT 2008 ACS on STM (Continued)




124-10 ANNEK 4-1-8 KEMULAS
 Dose, N=1-[1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)




124-11 ANNEK 4-1-9 KEMULAS
 Dose, N=1-[1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl]-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-12 ANNEK 4-1-10 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-13 ANNEK 4-1-11 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124 ANNEK 3 OF 10 KEMULAS COPYRIGHT 2008 ACS on STM (Continued)

124-15 ANNEK 4-1-12 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-16 ANNEK 4-1-13 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-17 ANNEK 4-1-14 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)



124-18 ANNEK 4-1-15 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)




124-19 ANNEK 4-1-16 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)




124-20 ANNEK 4-1-17 KEMULAS
 Dose, N=1-(4-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-4-piperidinyl)-N-(phenylmethyl)-N'-C1 (CA INDEX NAME)


124 ANSWER 3 OF 10 EXAMPLES COPYRIGHT 2009 ACS OF STM (CONTINUED)




RX 066663-70-3 HCAPL20
 CN 4-Piperidinone, 3-[15-methyl-2-[4-(trifluoromethylphenyl)-1H-imidazol-4-yl]acetyl]- (HCl) (CA INDEX NAME)




4S 4-Triperidinamine, 1-[[[5-methyl-2-[4-(trifluoromethyl)phenyl]-3H-imidazol-4-yl]methyl]-N-(phenylethyl)- (K2) (CA INDEX NAME)



428 4-[[5-*peridin*ylideneamino]-2-[[4-(*trifluoromethyl*)phenyl]-3*H*-imidazol-4-yl]methyl]-2-methyl-4,6-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5(1*H*)-yl] (CA 33055, HANSEN)




RD 066663-72-0 RCAFLEW
 CS 4-Piperidinamide, N-methyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-indazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




CS 4-Piperidinasine, N-ethyl-2-[[[5-methyl-2-[4-(3-trifluoromethyl)phenyl]-1H-indazol-4-yl]methoxy]-1-yl] (CA INDEX NAME)



124 ASHES 2 OF 10 BCADPUBS COPYRIGHT 2018 ACS on STN (Continued)



CS 4-Piperidindione, N-(cyclopropylmethyl)-3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methoxy]- (5CT) (CA INDEX NAME)




NS 44443-#1-0 HCA2LOS
CS 4-Tiperidinamine, N-cyclopentyl-2-[(5-methyl-2-[4-(trifluoromethyl)phenyl]-

[illegible]


NS 444465-83-2 07/21/05

CNCCc1c[nH]c2c1C=Cc3ccccc32


124 ANSWERS 2 OF 10 RECAPS COPYRIGHT 2009 ACS OR DTH (UNCLASSIFIED)




HN 666663-75-2 HCAPLED
 CN 4-Piperidinamine, 1-[(5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-N-propyl- (VCI) (CA INDEX NAME)




PD 666663-76-3 NCAPL001
 CD 4-Piperidinamine, N-(1-methylethyl)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (5CI) [CA INDEX NAME]



PR 464663-77-4 B04FL05
 CN 4-Piperidinoxime, 3-[[[5-methyl-2-[4-(trifluoromethyl)phenoxy]-3H-imidazol-4-yl]methoxy]-N-2-propanoyl- (R2C)] (CA INDEX NAME)




DOI: 10.1002/ps.2505
 CN: 6-Piperidolamine, N-butyl-3-[[5-methyl-2-[[4-(trifluoromethyl)phenyl]-1H-




EN 444463-79-6 HCAFLON
CM 6-Piperidylamine, N-cyclopropyl-3-[(5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-; (SCT) (CA 3400544)


124 ANSWER 3 OF 10 BCAD786 COPYRIGHT 2008 ACS on 6TH (Continued)




HS 444463-45-4 HCAPLUS
 CN 4-Piperidinaamine, 1-((15-methyl-2-((4-(trifluoromethyl)phenyl)-1*N*-indazol-4-yl)methyl)-8-(3-phenylpropyl)- (SCl) (CA INDEX NAME)



CS 6-Piperidinamine, N-(4-methoxyphenyl)-1-[(5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-6-yl)methyl]- (5CI) (CA INDEX NAME)




NO 666663-E7-6 NCAPLUS
 CR 4-Piperidinamide, N-((4-methoxyphenyl)methyl)-3-[[5-methyl-2-[[4-(trifluoromethyl)phenyl]-3-methyl]-6-methyl-2-pyridyl]amino]-2,5-pyridinedicarboxylate (1:1) (A INORG NAME)




800 666 663-60-2 07/2015

CCN(CC)CCOC1=CC=C(C=C1)C2=CC=CC=C2


124 ANSWER 3 OF 10 SCAPLES COPYRIGHT 2008 ACS ON STM (Continued)




124-1
CN 066663-11-5 SCAPLES
CN 4-Piperidinamine, N-((2,4-dichlorophenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-2
CN 066663-11-6 SCAPLES
CN 4-Piperidinamine, N-((2-chlorophenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)



124-3
CN 066663-11-4 SCAPLES
CN 4-Piperidinamine, N-((2-methoxyphenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-4
CN 066663-11-5 SCAPLES
CN 4-Piperidinamine, N-((2-methylphenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-5
CN 066663-11-7 SCAPLES


124 ANSWER 3 OF 10 SCAPLES COPYRIGHT 2008 ACS ON STM (Continued)




124-6
CN 066663-12-8 SCAPLES
CN 4-Piperidinamine, 1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-N-((4-chlorophenyl)methyl)- (XCI) (CA INDEX NAME)



124-7
CN 066663-12-9 SCAPLES
CN 4-Piperidinamine, N-((4-methoxyphenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)



124-8
CN 066663-13-1 SCAPLES
CN 4-Piperidinamine, N-((1,1'-biphenyl-3-yl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-9
CN 066663-13-3 SCAPLES
CN 4-Piperidinamine, N-((4-methylsulfonylphenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)

124 ANSWER 3 OF 10 SCAPLES COPYRIGHT 2008 ACS ON STM (Continued)


124-10
CN 066663-13-4 SCAPLES
CN 4-Piperidinamine, N-((1,3,5-trichlorophenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-11
CN 066663-13-5 SCAPLES
CN 4-Piperidinamine, N-((3,4-dichlorophenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)



124-12
CN 066663-13-6 SCAPLES
CN 4-Piperidinamine, N-((1-methylphenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-13
CN 066663-13-7 SCAPLES
CN 4-Piperidinamine, 1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-N-((2-nitrophenyl)methyl)- (XCI) (CA INDEX NAME)




124-14
CN 066663-13-8 SCAPLES
CN 4-Piperidinamine, N-((4-(4-methylsulfonylphenyl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)


124 ANSWER 3 OF 10 SCAPLES COPYRIGHT 2008 ACS ON STM (Continued)




124-15
CN 066663-13-9 SCAPLES
CN 4-Piperidinamine, N-((1,1'-biphenyl-3-yl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-16
CN 066663-14-0 SCAPLES
CN 4-Piperidinamine, 1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)-N-((4-phenoxyphenyl)methyl)- (XCI) (CA INDEX NAME)



124-17
CN 066663-14-1 SCAPLES
CN 4-Piperidinamine, N-((1,1'-biphenyl-3-yl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-18
CN 066663-14-2 SCAPLES
CN 4-Piperidinamine, N-((1,1'-biphenyl-3-yl)methyl)-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl)- (XCI) (CA INDEX NAME)




124-19
CN 066663-14-3 SCAPLES


124 ANSWER 3 OF 10 NCMPLES COPYRIGHT 2008 ACS on STM (Continued)
CN 4-Piperidin-4-yl-3-methoxy-2-[4-(trifluoromethyl)phenyl]-1H-imidazo-4-ylmethoxy]-1-NC1 (CA INDEX NAME)




AN 008464-1-7 NCMPLES
CN 4-Piperidin-4-yl-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazo-4-yl]methoxy]-1-[[4-(trifluoromethyl)phenyl]methyl]-1-NC1 (CA INDEX NAME)



AN 008464-21-1 NCMPLES
CN Urea, N-[[4-[[11-[[15-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazo-4-yl]methoxy]-1-piperidin-4-yl]amino]methyl]phenyl]-N'-phenyl- (PCI) (CA INDEX NAME)



AN 008471-74-9 NCMPLES
CN 3-Piperidin-4-yl-3-methoxy-2-[4-(trifluoromethyl)phenyl]-1H-imidazo-4-ylmethoxy]-1-[[4-(trifluoromethyl)phenyl]methyl]-1-NC1 (CA INDEX NAME)



AN 008471-75-2 NCMPLES
CN 3-Piperidin-4-yl-3-methoxy-2-[4-(trifluoromethyl)phenyl]-1H-imidazo-4-ylmethoxy]-1-[[4-(piperidin-4-yl)methyl]-1-NC1 (CA INDEX NAME)



124 ANSWER 4 OF 10 NCMPLES COPYRIGHT 2008 ACS on STM (Continued)


AN 01214710 NCMPLES
CN 1M-129146
TE Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)nicotinic acid analogues and their binding affinities for dopamine D2 and D3 receptors
AU Eadie, Doreen; Gaudin, Robert P.; Frenken, Ronald A.; Wu, Li.; Wadh, Robert P.
CN Department of Pathology-DET Center, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA
BO Bioorganic & Medicinal Chemistry (2003), 1(2), 2113-2122
PR Chem. Med. (2003) 2948-2956
SA Elsevier Science Ltd.
UT English

SA CHARACTER 136 291741
AN A series of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)nicotinic acid derivative, was prepared and their affinity for dopamine D2 and D3 receptors was measured using in vitro binding assays. Several nicotinic analogs were also prepared and tested for their affinity for dopamine D2 and D3 receptors. The results of receptor binding assays showed that the incorporation of an imidazole moiety between the PN ring and the amino nitrogen did not significantly increase the selectivity for dopamine D2 receptors, whereas the incorporation of an imidazole at the same region resulted in a total loss of affinity for both dopamine receptor subtypes after. The most selective compound in this series is 4, 7-dimethoxy-2-[2-(2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl-1, 2, 3, 4-tetrahydroquinoline, which has a 23 receptor affinity of 21 nM and a 10-fold selectivity for D3 vs. D2 receptors. The binding affinity for D2 and D3 receptors were also measured, and the results showed that several analogs were selective w/ receptor ligands.


12 076101-24-1P 076101-25-1P 076101-26-1P
076101-30-1P 076101-31-1P 076101-32-1P

AN INC (Pharmacological Activity) API (Synthetic preparation); AGO; Nicotinic, Nicotinic Acid; Preparation
CN 2-(2,3-dimethoxyphenyl)-1H-imidazo-4-methanone derivative
CN 076101-31-1P NCMPLES

CN Imipramine, 2-[[12-(2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)




AN 076101-33-5 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro-4, 7-dimethoxy- (PCI) (CA INDEX NAME)




AN 076101-33-7 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)

AN 076101-33-8 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)


124 ANSWER 5 OF 10 NCMPLES COPYRIGHT 2008 ACS on STM (Continued)




124 ANSWER 6 OF 10 NCMPLES COPYRIGHT 2008 ACS on STM (Continued)




AN 076101-34-8 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)



AN 076101-35-8 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)




AN 076101-36-8 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)




AN 076101-37-8 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)

AN 076101-37-9 NCMPLES
CN Imipramine, 2-[[12-(3-bromo-2,3-dimethoxyphenyl)-1H-imidazo-4-yl]methyl]-3, 2, 3, 4-tetrahydro- (PCI) (CA INDEX NAME)


124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



* STRUCTURE HIGHLIGHT TWO HANDED FOR DISPLAY - AVAILABLE VIA HYPERLINK

124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM




124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM




124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM




124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)




124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)



124 ANKER 5 OF 10 NCAPLUS COPYRIGHT 2008 ACS on STM (Continued)


[illegible]

174 ANSWER 4 OF 35 REAGENTS COPYRIGHT 2009 ACS ON 6/20 (Continued)




● 16: HCl

RN 116418-88-9 HCAPLUM
CN Pyridine, 1-((4-chloro-2-methoxyphenyl)-(8-iodooct-6-yl)methyl)-4-pyridinyl-, dihydrochloride (HCl) (CA INDEX NAME)




● 17: HCl

RN 116418-88-9 HCAPLUM
CN Pyridine, 1-((4-chloro-2-methoxyphenyl)-(8-iodooct-6-yl)methyl)-4-pyridinyl-, dihydrochloride (HCl) (CA INDEX NAME)



● 18: HCl


RN 191210-26-1 HCAPLUM
CN Pyridine, 1-((4-chloro-2-methoxyphenyl)-(8-iodooct-6-yl)methyl)-4-pyridinyl-, dihydrochloride (HCl) (CA INDEX NAME)



ASB ASSAY & OF 10 RECAPSULE CONFIDENTIAL STATE AIDS ACT (C) 2018

ASB The following are the names of the drugs and their chemical structures:


ASB 1. **1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828,**




EN 1446-83-83-5 NCAPL05
 Pterostilbene, 4-glyoxy-3-[(3-glyoxy-1*H*-imidazo[4-*g*]pyrrolyl)-1-yl]-, dihydrochloride (HCl) (ON (HCl) (HCl))



EN 1446-83-83-5 NCAPL05
 Pterostilbene, 3-[(2-[(2,4,6-trimethylphenyl)-1*H*-imidazo[4-*g*]pyrrolyl)-1-yl]-2,4,6-trimethyl-, dihydrochloride (HCl) (ON (HCl) (HCl))


[illegible][illegible]

124 ANSWER 7 OF 10 NOCAPS COPYRIGHT 2008 ACS on STM (Continued)



● 1: HCl


RR 179320-27-5 NOCAPS
CN Piperidine, 4-((4-fluorophenyl)-5-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)



RR 179320-28-6 NOCAPS
CN Piperidine, 4-((4-fluorophenyl)-5-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)

CN 1

RR 179320-27-5
CN C22 H24 F N3




CN 2

RR 115-16-7
CN C4 H4 O4

Double bond geometry as shown:



RR 179320-28-7 NOCAPS
CN Piperidine, 4-((4-fluorophenyl)-5-[[2-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)




124 ANSWER 7 OF 10 NOCAPS COPYRIGHT 2008 ACS on STM (Continued)



RR 179320-28-6 NOCAPS
CN Piperidine, 4-[[2-[[2-[[4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-5-[[2-2-methoxyphenyl]-1H-imidazol-4-yl)methyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)

CN 1

RR 179320-28-6
CN C22 H24 F N3



CN 2

RR 115-16-7
CN C4 H4 O4


Double bond geometry as shown:



RR 179320-44-6 NOCAPS
CN Piperidine, 4-((4-methyl-2-phenyl-1H-imidazol-5-yl)methyl)-4-pyrimidinyl)- (HCl) (CA INDEX NAME)



RR 179320-43-9 NOCAPS
CN Piperidine, 4-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-5-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)



● 2: HCl

RR 179320-44-0 NOCAPS
CN Piperidine, 4-((4-methyl-2-phenyl-1H-imidazol-4-yl)methyl)-4-pyrimidinyl)- (HCl) (CA INDEX NAME)

124 ANSWER 7 OF 10 NOCAPS COPYRIGHT 2008 ACS on STM (Continued)

RR 179320-30-0 NOCAPS
CN Piperidine, 4-[[2-[[2-[[4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-5-[[2-2-methoxyphenyl]-1H-imidazol-4-yl)methyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)

CN 1

RR 179320-30-3
CN C22 H24 F N3



CN 2

RR 115-16-7
CN C4 H4 O4

Double bond geometry as shown:




RR 179320-31-1 NOCAPS
CN Piperidine, 4-((4-fluorophenyl)-5-[[2-imidazol-4-yl)methyl]-4-pyrimidinyl)-5-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)



● 1: HCl

RR 179320-32-2 NOCAPS
CN Piperidine, 4-((4-fluorophenyl)methyl)-1-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)-5-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)




● 2: HCl

RR 179320-35-5 NOCAPS
CN Piperidine, 4-[[2-[[2-[[4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-5-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)

124 ANSWER 7 OF 10 NOCAPS COPYRIGHT 2008 ACS on STM (Continued)




RR 179320-44-6 NOCAPS
CN Piperidine, 4-[[2-[[2-[[4-methylphenyl)-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-5-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)



RR 179320-28-6 NOCAPS
CN Piperidine, 4-[[2-[[2-[[4-methylphenyl)-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-5-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)



RR 179320-41-1 NOCAPS
CN Piperidine, 4-[[2-[[2-[[4-methylphenyl)-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-5-[[2-[[2-phenyl-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl]-1H-imidazol-4-yl)methyl]-4-pyrimidinyl)- (HCl) (CA INDEX NAME)



RR 179320-55-4 NOCAPS
CN 4-methylpiperidine, 4-((4-methyl-2-phenyl-1H-imidazol-4-yl)-2-pyrimidinyl)- (HCl) (CA INDEX NAME)



RR 179320-46-0 NOCAPS
CN Piperidine, 4-((4-methyl-2-phenyl-1H-imidazol-4-yl)methyl)-4-pyrimidinyl)- (HCl) (CA INDEX NAME)

178920-45-09 178920-46-09
 PL= BAC (Biological activity or effector, except adenosine); BSB (Biological
 study, unclassified); BSW (Synthetic preparation); TRU (Therapeutic use);
 BISO (Biological study); BREP (Preparation); BSSB (Base)
 [prep. of 3-phenyl-4(3)-aminomethylimidazole as dopamine receptor
 ligand]
 See, also: 178920-45-09

CS Piperidine, 1-[12-phenyl-18-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (VCI) (CA INDEX NAME)



03 Piperidine, 4-phenyl-1-[12-phenyl-1H-imidazol-4-yl)methyl]-,



CS Isoquinoline, 1,2,3,4-tetrahydro-2-[1-(2-phenyl-1H-imidazol-4-yl)methyl]-,



Isosqualine, 2-[12-(3,3-dimethoxyphenyl)-3H-indolol-4-yl]ethyl-1,2,3,4-tetrahydro-, dihydrochloride (923) (CA INDEX NAME)



124 ANGELOS E. ET AL. REAPPLIED COPYRIGHT 2009 ACS OR STM (CC-BY-NC-ND)

AN	144635-54-3	ANILIN
CE	Piperidine, 1-[[[2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl]methyl]-4-	



CE Piperidine, 1-[(2-phenoxy-1*H*-imidazol-4-yl)methyl]-, dihydrochloride (HCl)



CH Piperidine, 1-[(2-{[2,3-dimethoxyphenyl]-18-imidazol-4-yl[methyl]-4-(2-



CN Pyridine, 2-[1-[(2-phenyl-1*H*-indoliz-4-yl)methyl]-4-piperidyl]-, dihydrochloride (HCl) (CN 706978).



124 ANSWER 9 OF 10: BCB256 COPYRIGHT 2008 ACS, INC. 5TH

TI 2-Phenyl-4-(aminometh

AS Thangkauf, Andrew; Hutchings, Alan; Peterson, John, Cornfield, Linda, Meade, Robin; Hoston, Kevin; Harris, Kristine; Ross, Philip C., Gerber, Karen; Ramabhadran, T. V.

CA Department of Chemistry, Neurogen Corporation, Branford, CT, 06405, USA
SD Journal of Medicinal Chemistry (1995), 38(12), 2251-5
CODEN: JMCMAA; ISSN: 0022-2623

AB A series of 2-phenyl-2-(aminoethyl)imidazoles (IM-imidazole-2-methanamines) were designed as conformationally restricted analogs of the dopamine D2 selective benzamide antipsychotics. The title compounds were synthesized and tested for bioactivity at [³H]YM-57151 binding in cloned African green monkey dopamine D2 receptor preps. The binding affinity data thus obtained were compared against that of the benzamide and a

17 164670-70-49
 SL: NAC (Biological activity or effector, except adverse); BSA (Biologic study, unclassified); SDN (Synthetic preparation); BDC (Biological

study); 0022 (Preparation
(preparation of 18-imidazole-4-methanamines as antipsychotics)
RU 144470-70-4 NCAFLAN
RU 144470-70-4 NCAFLAN
RU 144470-70-4 NCAFLAN

● **2014**

17 164670-63-3P 164670-65-3P 164670-66-2P
164670-67-1P
BL, DPE (Synthetic preparation); DPEP (Preparation)

4-Piperidinol, 4-(4-chlorophenyl)-1-[(2-pyrenyl)-1*H*-imidazol-5-ylmethyl]-

● **2013**

039 164670-65-9 BOCALUG

CH 28-Benzimidazol-2-yl-
vinylmethyl-4-piperid

NAME: _____

On 1

-> b hcao
FILE 'HCAOLD' ENTERED AT 18:20:22 ON 03 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR SIN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

PRK-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

-> d all 126 tot

```

134 ANSWER 1 OF 1 RECORDS COMPLETED 2008 APR 06 AM
15 C811-47-0 CASILL
17 oligomeric(hydroxy- and -tetrahydroglyoxal)-4-one
19 Compound, Line = 0
21 Data:
23 C811-47-0, K1ND, DATE
-----
25 05-00-116410 1958
27 305-47-1 13070-47-1 13070-47-1 16419-51-1 21043-47-4
11640-47-4 130440-01-8

```

-> b reg;d ide can 127
FILE 'REGISTRY' ENTERED AT 18:20:41 ON 03 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7
DICTIONARY FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

10) ANSWER 1 OF 1 RESULTS COPYRIGHT 2006 ACS OR RSC
 00 131468-41-0 BUCLEFIN
 03 Entered STD 08 Dec 1991
 04 Paperchem, 1-[2-(1-phenylmethyl-4-oxo-5-ylidene-1H-1,2,4-triazol-3-yl)ethyl]-1H-1,2,4-triazole (NCT) (C8 EXR00)
 05 NAME
 06 C18 H13 N5
 07 SM
 08 CAS#
 09 WITH P144: REILLYVIEW*, CA, CAGLA, CAPUGA, CHERMON, GUNFIELD
 10 [*File contains numerically searchable property data]



PROPERTY DATA AVAILABLE IN THE "PROP" FORMAT

2 REFERENCES IN FILE CA (1987 TO DATE)
 2 REFERENCES IN FILE CAPUGA (1987 TO DATE)
 1 REFERENCES IN FILE CAGLA (1987 TO DATE)

REFERENCE 1: 51-2292

REFERENCE 2: 51-2249

-> d his

(FILE 'HOME' ENTERED AT 17:28:05 ON 03 MAR 2008)

FILE 'HCAPLUS' ENTERED AT 17:28:41 ON 03 MAR 2008
L1 1 US20060154917/PN

FILE 'REGISTRY' ENTERED AT 17:28:58 ON 03 MAR 2008

FILE 'HCAPLUS' ENTERED AT 17:28:58 ON 03 MAR 2008
L2 TRA L1 1- RN : 227 TERMS

FILE 'REGISTRY' ENTERED AT 17:28:58 ON 03 MAR 2008
L3 227 SEA L2
L4 191 L3 AND NCNC2/ES
L5 STR
L6 1 L5
L7 908950 NCNC2/ES
L8 3 L5 SAM SUB=L7
L9 739 L5 FULL SUB=L7
SAV TEM J401C1GXIII/A L9
L10 161 L9 AND L3
L11 578 L9 NOT L10

FILE 'HCAPLUS' ENTERED AT 17:33:37 ON 03 MAR 2008
L12 1 L10
L13 66 L11
L14 43 L13 AND (PD<-20030703 OR AD<-20030703 OR PRD<-20030703)
L15 23 L13 AND PD<-20020703
L16 20 L14 NOT L15
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 17:36:05 ON 03 MAR 2008
L17 331 E1-331
L18 101 E332-432
L19 22 L17 AND (C22H25N3O OR C20H27F3N4 OR C21H22FN3 OR C24H29N3O OR C
L20 23 L18 AND (C21H22FN3 OR C20H22N4 OR C19H19N3 OR C23H26BRN3O4 OR C
L21 28 L19,L20

FILE 'HCAPLUS' ENTERED AT 18:14:52 ON 03 MAR 2008
L22 10 L21
L23 0 L22 AND L1
L24 10 L22 AND L14-16

FILE 'HCAOLD' ENTERED AT 18:15:25 ON 03 MAR 2008
L25 0 L10
L26 1 L11
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 18:15:45 ON 03 MAR 2008
L27 1 E433

FILE 'HCAOLD' ENTERED AT 18:16:11 ON 03 MAR 2008
SEL AN L26
EDIT E434 /AN /OREF

FILE 'HCAPLUS' ENTERED AT 18:16:35 ON 03 MAR 2008
L28 2 E434
L29 12 L24,L28

=> => b reg

FILE 'REGISTRY' ENTERED AT 09:56:25 ON 04 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAR 2008 HIGHEST RN 1006431-93-1
 DICTIONARY FILE UPDATES: 3 MAR 2008 HIGHEST RN 1006431-93-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 19


L4 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
 L5 (908950)SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES
 L6 739 SEA FILE=REGISTRY SUB=L5 SSS FUL L4
 L7 STR



NODE ATTRIBUTES:
 CONNECT IS M3 RC AT 4
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
 L9 175 SEA FILE=REGISTRY SUB=L6 SSS FUL L7

100.0% PROCESSED 739 ITERATIONS
 SEARCH TIME: 00.00.01

175 ANSWERS

```
-> b hcap
FILE 'HCAPLUS' ENTERED AT 09:56:38 ON 04 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 4 Mar 2008 VOL 148 ISS 10
FILE LAST UPDATED: 3 Mar 2008 (20080303/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d bib abs hitstr l14 tot
```


114 **ASSAYER & OF A NUCLEUS COPYRIGHT 2020 ACS on STM**
 AN 1022 177022 NUCLEUS
 ON 137179153
 IT Preparation of 4-(substituted)-3-(substituted) azanodiazole derivatives and
 4-(substituted)-5-(substituted) azanodiazole derivatives, new classes of dopamine
 receptor modulators, specific ligands
 DA Thirumangalakudi, Arundhan, Rajagopal M. V., Var, Jay, Maheshwari, John H.
 MA Bangalore Corporation, India
 ON 1022 177022 37 pp. Cont. of U.S. Ser. No. 241,169
 ON 1022 177022
 SA English
 AN 1022 177022

PATENT NO.	INNO	DATE	APPLICATION NO.	DATE
JP 2003-011913	A1	20030129	2010-0019862	20020918 ---
JP 2003-011914	A1	20030129		
JP 2003-011915	A1	20030129		
JP 2003-011916	A1	20030129		
JP 2003-011917	A1	20030129		
JP 2003-011918	A1	20030129		
JP 2003-011919	A1	20030129		
JP 2003-011920	A1	20030129		
JP 2003-011921	A1	20030129		
JP 2003-011922	A1	20030129		
JP 2003-011923	A1	20030129		
JP 2003-011924	A1	20030129		
JP 2003-011925	A1	20030129		
JP 2003-011926	A1	20030129		
JP 2003-011927	A1	20030129		
JP 2003-011928	A1	20030129		
JP 2003-011929	A1	20030129		
JP 2003-011930	A1	20030129		
JP 2003-011931	A1	20030129		
JP 2003-011932	A1	20030129		
JP 2003-011933	A1	20030129		
JP 2003-011934	A1	20030129		
JP 2003-011935	A1	20030129		
JP 2003-011936	A1	20030129		
JP 2003-011937	A1	20030129		
JP 2003-011938	A1	20030129		
JP 2003-011939	A1	20030129		
JP 2003-011940	A1	20030129		
JP 2003-011941	A1	20030129		
JP 2003-011942	A1	20030129		
JP 2003-011943	A1	20030129		
JP 2003-011944	A1	20030129		
JP 2003-011945	A1	20030129		
JP 2003-011946	A1	20030129		
JP 2003-011947	A1	20030129		
JP 2003-011948	A1	20030129		
JP 2003-011949	A1	20030129		
JP 2003-011950	A1	20030129		
JP 2003-011951	A1	20030129		
JP 2003-011952	A1	20030129		
JP 2003-011953	A1	20030129		
JP 2003-011954	A1	20030129		
JP 2003-011955	A1	20030129		
JP 2003-011956	A1	20030129		
JP 2003-011957	A1	20030129		
JP 2003-011958	A1	20030129		
JP 2003-011959	A1	20030129		
JP 2003-011960	A1	20030129		
JP 2003-011961	A1	20030129		
JP 2003-011962	A1	20030129		
JP 2003-011963	A1	20030129		
JP 2003-011964	A1	20030129		
JP 2003-011965	A1	20030129		
JP 2003-011966	A1	20030129		
JP 2003-011967	A1	20030129		
JP 2003-011968	A1	20030129		
JP 2003-011969	A1	20030129		
JP 2003-011970	A1	20030129		
JP 2003-011971	A1	20030129		
JP 2003-011972	A1	20030129		
JP 2003-011973	A1	20030129		
JP 2003-011974	A1	20030129		
JP 2003-011975	A1	20030129		
JP 2003-011976	A1	20030129		
JP 2003-011977	A1	20030129		
JP 2003-011978	A1	20030129		
JP 2003-011979	A1	20030129		
JP 2003-011980	A1	20030129		
JP 2003-011981	A1	20030129		
JP 2003-011982	A1	20030129		
JP 2003-011983	A1	20030129		
JP 2003-011984	A1	20030129		
JP 2003-011985	A1	20030129		
JP 2003-011986	A1	20030129		
JP 2003-011987	A1	20030129		
JP 2003-011988	A1	20030129		
JP 2003-011989	A1	20030129		
JP 2003-011990	A1	20030129		
JP 2003-011991	A1	20030129		
JP 2003-011992	A1	20030129		
JP 2003-011993	A1	20030129		
JP 2003-011994	A1	20030129		
JP 2003-011995	A1	20030129		
JP 2003-011996	A1	20030129		
JP 2003-011997	A1	20030129		
JP 2003-011998	A1	20030129		
JP 2003-011999	A1	20030129		
JP 2003-012000	A1	20030129		
JP 2003-012001	A1	20030129		
JP 2003-012002	A1	20030129		
JP 2003-012003	A1	20030129		
JP 2003-012004	A1	20030129		
JP 2003-012005	A1	20030129		
JP 2003-012006	A1	20030129		
JP 2003-012007	A1	20030129		
JP 2003-012008	A1	20030129		
JP 2003-012009	A1	20030129		
JP 2003-012010	A1	20030129		
JP 2003-012011	A1	20030129		
JP 2003-012012	A1	20030129		
JP 2003-012013	A1	20030129		
JP 2003-012014	A1	20030129		
JP 2003-012015	A1	20030129		
JP 2003-012016	A1	20030129		
JP 2003-012017	A1	20030129		
JP 2003-012018	A1	20030129		
JP 2003-012019	A1	20030129		
JP 2003-012020	A1	20030129		
JP 2003-012021	A1	20030129		
JP 2003-012022	A1	20030129		
JP 2003-012023	A1	20030129		
JP 2003-012024	A1	20030129		
JP 2003-012025	A1	20030129		
JP 2003-012026	A1	20030129		
JP 2003-012027	A1	20030129		
JP 2003-012028	A1	20030129		
JP 2003-012029	A1	20030129		
JP 2003-012030	A1	20030129		
JP 2003-012031	A1	20030129		
JP 2003-012032	A1	20030129		
JP 2003-012033	A1	20030129		
JP 2003-012034	A1	20030129		
JP 2003-012035	A1	20030129		
JP 2003-012036	A1	20030129		
JP 2003-012037	A1	20030129		
JP 2003-012038	A1	20030129		
JP 2003-012039	A1	20030129		
JP 2003-012040	A1	20030129		
JP 2003-012041	A1	20030129		
JP 2003-012042	A1	20030129		
JP 2003-012043	A1	20030129		
JP 2003-012044	A1	20030129		
JP 2003-012045	A1	20030129		
JP 2003-012046	A1	20030129		
JP 2003-012047	A1	20030129		
JP 2003-012048	A1	20030129		
JP 2003-012049	A1	20030129		
JP 2003-012050	A1	20030129		
JP 2003-012051	A1	20030129		
JP 2003-012052	A1	20030129		
JP 2003-012053	A1	20030129		
JP 2003-012054	A1	20030129		
JP 2003-012055	A1	20030129		
JP 2003-012056	A1	20030129		
JP 2003-012057	A1	20030129		
JP 2003-012058	A1	20030129		
JP 2003-012059	A1	20030129		
JP 2003-012060	A1	20030129		
JP 2003-012061	A1	20030129		
JP 2003-012062	A1	20030129		
JP 2003-012063	A1	20030129		
JP 2003-012064	A1	20030129		
JP 2003-012065	A1	20030129		
JP 2003-012066	A1	20030129		
JP 2003-012067	A1	20030129		
JP 2003-012068	A1	20030129		
JP 2003-012069	A1	20030129		
JP 2003-012070	A1	20030129		
JP 2003-012071	A1	20030129		
JP 2003-012072	A1	20030129		
JP 2003-012073	A1	20030129		
JP 2003-012074	A1	20030129		
JP 2003-012075	A1	20030129		
JP 2003-012076	A1	20030129		
JP 2003-012077	A1	20030129		
JP 2003-012078	A1	20030129		
JP 2003-012079	A1	20030129		
JP 2003-012080	A1	20030129		
JP 2003-012081	A1	20030129		
JP 2003-012082	A1	20030129		
JP 2003-012083	A1	20030129		
JP 2003-012084	A1	20030129		
JP 2003-012085	A1	20030129		
JP 2003-012086	A1	20030129		
JP 2003-012087	A1	20030129		
JP 2003-012088	A1	20030129		
JP 2003-012089	A1	20030129		
JP 2003-012090	A1	20030129		
JP 2003-012091	A1	20030129		
JP 2003-012092	A1	20030129		
JP 2003-012093	A1	20030129		
JP 2003-012094	A1	20030129		
JP 2003-012095	A1	20030129		
JP 2003-012096	A1	20030129		
JP 2003-012097	A1	20030129		
JP 2003-012098	A1	20030129		
JP 2003-012099	A1	20030129		
JP 2003-012100	A1	20030129		
JP 2003-012101	A1	20030129		
JP 2003-012102	A1	20030129		
JP 2003-012103	A1	20030129		
JP 2003-012104	A1	20030129		
JP 2003-012105	A1	20030129		
JP 2003-012106	A1	20030129		
JP 2003-012107	A1	20030129		
JP 2003-012108	A1	20030129		
JP 2003-012109	A1	20030129		
JP 2003-012110	A1	20030129		
JP 2003-012111	A1	20030129		
JP 2003-012112	A1	20030129		
JP 2003-012113	A1	20030129		
JP 2003-012114	A1	20030129		
JP 2003-012115	A1	20030129		
JP 2003-012116	A1	20030129		
JP 2003-012117	A1	20030129		
JP 2003-012118	A1	20030129		
JP 2003-012119	A1	20030129		
JP 2003-012120	A1	20030129		
JP 2003-012121	A1	20030129		
JP 2003-012122	A1			

114 ANSWER 7 OF 8 HOMPLUS COPYRIGHT 2008 ACS on STM (CONTINUED)

TX	C13556-01-59	RL: DAC (Dermatological activity); SBN (Synthetic preparations); THU (Therapeutic use); NIGL (Biological study); UNED (Preparation); UNED (Study)
		(Preparation of substituted imides, pyrazoles and amides as high affinity C3a receptor modulators)
PH	C13556-01-6	NCAPL16
ON		Immunoglobulin, 2-(1-butyl-2-phenyl-1H-imidazol-5-yl)methyl-1H-cyclopentyl-1,3,3,6-tetrahydro-6-oxo-1,2,3,4-tetrahydropyrimidin-2(1H)-one (CA UNEDX SPARK)



114 ARTICLE 9 OF 9 | SCAPULS COPYRIGHT 2009 ACS OR ETH

AN	1956:467020	NONRUS
AN	125:114630	
TI	Certain 6- <i>o</i> -methyl-2-substituted muscarinic derivatives and 2- <i>o</i> -methyl-6-substituted muscarinic derivatives, new classes of dopamine receptor subtype specific ligands	
DE	Thurberk, Andrew; Horvath, Raymond E.; Yuen, Jan; Peterson, John H. Neurologic Characterization, SRI NCT Int. Appl., 54 pp. COTTON P19030	
DT	Patent	
LA	English	

[illegible]


AB Disclosed are compounds (I), wherein R₁ represents optionally substituted aryl, heteroaryl, alkyl, or cycloalkyl groups; R₂, R₃, and R₄ are optionally substituted alkyl or carbocyclic; R₅ and R₆ are organic or inorganic substituents which may together form ring structures; n is zero, one or two; and R₇ and R₈ are organic or inorganic substituents; and the pharmaceutically acceptable addition salts thereof, which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment

314 ANSWER 8 OF 9 NCAPLUS COPYRIGHT 2014 ACS on STN (Continued)

of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Specifically, 2-(2-phenyl-4-(5)-[4-(2-pyridindyl)piperazine-1-yl)methyl]imidazole dihydrochloride was prepared and was shown to bind to the dopamine D4 receptor site (K_i = 1211, 8200, 2.2 for M2, M3, D4 binding sites, respec-

12 179332-44-6P
NA= NAC (Biological activity or effector, except address); BS (Biological study, unclassified); AP (Asynthetic preparation); TH (Therapeutic use); BSL (Biological study), PREP (Preparation); USES (Uses)
indexation.org.uk/de/na/bs/ap/th/uses/

(preparation of imidazole derivative as dopamine receptor partial agonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)
 IN 179332-44-6 NCAMFUS
 CN Piperidine, 1-[1-(methoxyl-2-phenoxyl-1H-imidazol-5-yl)methyl]-4-(2-phenoxymethyl)- (CA INDEX NAME)




124 ASSMER, 9 OF 9 BCAPLUS COPYRIGHT 2000 ACS on STM

TI Headlines of 4-imidazolidinone and 6-imidazolidinone derivatives
 AD AL-SH-SAMAD, THABHA F.; NASHAR, ADE K.; SAUD, ABDO-KHABAB; MOHAMMAD M.

05 Fac. Sci., Mansoura Univ., Mansoura, Egypt
 30 Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1983), 22B(5), 481-3
 CODEN: IJOCDE. 1983. 2376-1488.

OCEN: 12086; ISSN:
BT Journal



AB Mannich reaction of imidazolidinones I ($R = Ph$, 2-MeC₆H₄, 4-MeC₆H₄) with piperidine and morpholine gave the N-Mannich bases whereas imidazolidinones II gave the C-Mannich bases. Reaction of II with PhNH₂ or MeNH₂ gave imidazolidinones III ($R_1 = Ph$, Me). Treating I with Me₂SO₄, acrylonitrile, or Ac₂O gave the N-alkylation or N-acylation products:
 IT 87191-51c/79

RL: PCT (Reactant); SPH (Synthetic preparation); PREP (Preparation); PACT

```

(Reactant or reagent)
  (preparation and reaction of, with thiocresol)
NN 81151-51-7 SCAPLES
CN 66-114-01-01, 1,5-dihydro-3,3,5-triphenyl-5-(1-piperidinyl)-
  (CA INDEX NAME)

```



IT 27751-53-10 27751-55-10
 RL: 50P (Synthetic preparation); 902P (Preparation)

(preparation of)
 47791-83-5 EGAFIAB
 68-144-01-4-000, 1,5-dihydro-3-(3-methylphenyl)-2,5-diphenyl-5-(1-piperidinylmethyl)- (CA INDEX NAME)



48-Imidazol-4-one, 1,5-dihydro-3-(4-methylphenyl)-2,5-diphenyl-5-(3-piperidinylmethyl)- (CA INDEX NAME)

114 ANSWER 3 (OF 3) HCPMULB: COPYRIGHT 2004 ACS INC. STM (CONTINUED)



-> d bib abs hitrn fhitstr 115 tot

[illegible]

135 ANDROS, 1 OF 2 HCAPULE, COPYRIGHT 2018 ACS ON BTH (C08134444)
CN Carbonic acid, N-[5-[[4-(3,3-dimethyl-1-oxo-2-oxo-7-oxaspiro[4.5]dec-7-yl)-1-piperidinyl]carbonyl]-2-phenyl-1-(phenylmethyl)-1H-imidazol-4-yl]-, 1,1-dimethylethyl ester (CS, INDEX NAME)





RE:INT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

[illegible]

135 ABSTRACT 2 OF 2. NCAR035. COPYRIGHTED 1994 ACS on STM (Continued).
N-tetrapeptidylarginine affords 11. Over 1600 compounds I were prepared. Most
of these exhibit low IC_{50} values for inhibiting ^{125}I -labeled histamine binding assay
that is less than 1 μ M. Compds. I can be administered alone or in
combination with one or more other CNS agents to potentiate the effects
the other CNS agent(s). Pharmaceutical compds and methods for treating
the mentioned above disorders are provided, as are methods for using such
lipids for detecting histamine H_2 receptors (e.g., receptor localization

13	ATC01AD05 2014-04-01-2019-03-31 016474-00-00 ML: DMC (Pharmacological activity); SEM (Synthetic preparation); TNU (Therapeutic use); BDL (Biological study); PPD (Preparation); USES (Uses) (Preparation of thiazole amides, imidazole amides and related analogs containing R3 receptor modulators)
12	0164-00-00-00 ML: DMC (Pharmacological activity); SEM (Synthetic preparation); TNU (Therapeutic use); BDL (Biological study); PPD (Preparation); USES (Uses) (Preparation of thiazole amides, imidazole amides and related analogs containing R3 receptor modulators)
06	4-Piperidinecarboxamide, N-(8-methyl-1-[11-ethyl-4-methyl-2-(1-septahenyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-1-yl]-11-ethyl-1H-imidazole-5-carboxylate)

[illegible]

The title compound 2 (H) = (methylsubstituted alkyl, alkyl or cycloalkyl)alkyl, de R taken together with R2 as R4 can form (methylsubstituted 4-m numbered heterocycloalkyl); R2 = alkyl, alkyl, cycloalkyl, or cycloalkyl, de R taken together with R2 as R4 can form (methylsubstituted 4-m numbered heterocycloalkyl); R2 = H, alkyl, alkyl, cycloalkyl, or cycloalkyl, de R taken together with R2 as R4 can form (methylsubstituted 4-m numbered heterocycloalkyl); R4 = R2 or taken together with R2, R3 or R3 can form (methylsubstituted 4-m numbered heterocycloalkyl); R2 = CH₃, CH₃CH₂, CH₃CH₂CH₂, CH₃CH₂CH₂CH₂, CH₃CH₂CH₂CH₂CH₂, or (methylsubstituted 2, naphthyl, biphenyl, 5-13 numbered heterocyc, with precursor) which may be used to modulate binding potency to histamine H3 receptors in vivo and in vitro. The compound may be used in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated nonprimate animals and livestock animals, where the compound is used in combination with a pharmaceutically acceptable carrier.

```
-> b uspatall
FILE 'USPATFULL' ENTERED AT 09:58:24 ON 04 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 09:58:24 ON 04 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:58:24 ON 04 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

-> d bib abs hitstr 120 tot
```


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 435558-0-80
 [preparation of substituted imidazoles, pyrazoles and amides as high
 affinity 5A receptor modulators]
 NO 435558-0-5 EUGENIUM
 CS Isosulquimine, 2-((1-benzyl-2-phenyl-1H-imidazol-5-yl)methyl)-1-cyclopropyl-
 1,2,3,4-tetrahydropyridine [CA INDEX NAME]

substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate the receptor activity *in vivo* or *in vitro*, and are particularly useful in the treatment of disorders associated with pathological GABA receptor activation in humans, domesticated companion animals and livestock animals. Pharmacological compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

CA8 INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 612249-23-79
 [preparation of new aryl imidazoles and related comds. as GSA receptors
 modulators]
 IN 611249-23-7 USPATENTUAL
 CS Isaqueimide, 3-((12-(2,3-dihydro-5H-inden-2-yl)-2-phenyl-2H-imidazol-5-
 yl)methyl)-1,2,3,4-tetrahydro-1-(2-methylphenyl)piperazine (CA INDEX NAME)


[illegible]

AA The invention comprises novel minipiperidine derivatives, a process for their manufacture, pharmaceutical compositions and the use of each compound in medicine. In particular, the compounds of formula I prevent the human immunodeficiency virus (HIV) from interacting with the interaction of the viral envelope protein gp120 with a chemokine receptor on the cell surface. The compounds of this invention may be advantageously used as therapeutic agents for the treatment of diseases caused by the human immunodeficiency virus (HIV), either alone or in combination with other HIV inhibitors or HIV viral replication or with pharmacoenhancers.

```

CAS INDEXING IS RELIABLE FOR THIS ENTRY.
1 044443-31-OP, 1-benzyl-1-[1-[(3-benzyl-5-methyl-2-(4-
(trifluoromethyl)phenyl)-3H-imidazo[4,5-g]methyl)-6-piperidyl]-2-
methylpiperazine
(MW INHIBITOR; preparation of indolizylalkyl-aminopyrrolidines as
inhibitors)
MW 044443-31-0 C00007FULL
CAS Drew, N-3-methyl-N-[1-[(1-[(2-methyl-1-phenylethyl)-2-(4-
(trifluoromethyl)phenyl)-3H-imidazo[4,5-g]methyl)-6-piperidyl]-N-
(3-phenylmethyl)-N-1]-(CAZ INDEX NAME)

```



-> d bib abs hitrn fhitstr 122 tot

122 ANSWER 2 OF 2 USEFUL on 6/16

CAS INDEXING IS AVAILABLE FOR THIS ENTRY

132 ANSWER 1 OF 2 GIBBATTI, GR NTH (CONCLUDED)

122 ANSWER 2 OF 2 95497611 on 5/18 (Continued)

-> d his

(FILE 'HOME' ENTERED AT 09:45:28 ON 04 MAR 2008)

FILE 'HCAPLUS' ENTERED AT 09:46:19 ON 04 MAR 2008

L1 1 US20060184917/PN

FILE 'REGISTRY' ENTERED AT 09:46:50 ON 04 MAR 2008

FILE 'HCAPLUS' ENTERED AT 09:46:52 ON 04 MAR 2008

L2 TRA L1 1- RN : 227 TERMS

FILE 'REGISTRY' ENTERED AT 09:46:53 ON 04 MAR 2008

L3 227 SEA L2
ACT J401C1CXIII/A

L4 STR

L5 (908950)SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES

L6 739 SEA FILE=REGISTRY SUB=L5 SSS FUL L4

L7 STR L4

L8 10 L7 SAW SUB=L6

L9 179 L7 FULL SUB=L6

SAW TEM J401C1S1/A L9

L10 161 L9 AND L3

L11 14 L9 NOT L10

FILE 'HCAPLUS' ENTERED AT 09:51:17 ON 04 MAR 2008

L12 1 L10

L13 11 L11

L14 9 L13 AND (PD<-20030703 OR AD<-20030703 OR AD<-20030703)

L15 2 L13 NOT L14

FILE 'HCAOLD' ENTERED AT 09:54:07 ON 04 MAR 2008

L16 0 L9

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 09:54:26 ON 04 MAR 2008

L17 16 L9

L18 1 L17 AND L1

L19 15 L17 NOT L18

L20 14 L19 AND L11

L21 1 L19 AND L10

L22 2 L18,L21

=>